Metabolites 2013, 3(3), 658-672; doi:10.3390/metabo3030658
Article

Global Metabolomics Reveals Urinary Biomarkers of Breast Cancer in a MCF-7 Xenograft Mouse Model

1email, 1email, 1email, 1email, 2email, 3email and 1,* email
Received: 21 June 2013; in revised form: 2 August 2013 / Accepted: 2 August 2013 / Published: 7 August 2013
(This article belongs to the Special Issue Cancer Metabolomics)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Global metabolomics analysis has the potential to uncover novel metabolic pathways that are differentially regulated during carcinogenesis, aiding in biomarker discovery for early diagnosis and remission monitoring. Metabolomics studies with human samples can be problematic due to high inter-individual variation; however xenografts of human cancers in mice offer a well-controlled model system. Urine was collected from a xenograft mouse model of MCF-7 breast cancer and analyzed by mass spectrometry-based metabolomics to identify metabolites associated with cancer progression. Over 10 weeks, 24 h urine was collected weekly from control mice, mice dosed with estradiol cypionate (1 mg/mL), mice inoculated with MCF-7 cells (1 × 107) and estradiol cypionate (1 mg/mL), and mice dosed with MCF-7 cells (1 × 107) only (n = 10/group). Mice that received both estradiol cypionate and MCF-7 cells developed tumors from four weeks after inoculation. Five urinary metabolites were identified that were associated with breast cancer; enterolactone glucuronide, coumaric acid sulfate, capric acid glucuronide, an unknown metabolite, and a novel mammalian metabolite, “taurosebacic acid”. These metabolites revealed a correlation between tumor growth, fatty acid synthesis, and potential anti-proliferative effects of gut microbiota-metabolized food derivatives. These biomarkers may be of value for early diagnosis of cancer, monitoring of cancer therapeutics, and may also lead to future mechanistic studies.
Keywords: metabolomics; biomarker; MCF-7; breast cancer; xenograft
PDF Full-text Download PDF Full-Text [950 KB, Updated Version, uploaded 8 August 2013 15:22 CEST]
The original version is still available [966 KB, uploaded 7 August 2013 16:35 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Johnson, C.H.; Manna, S.K.; Krausz, K.W.; Bonzo, J.A.; Divelbiss, R.D.; Hollingshead, M.G.; Gonzalez, F.J. Global Metabolomics Reveals Urinary Biomarkers of Breast Cancer in a MCF-7 Xenograft Mouse Model. Metabolites 2013, 3, 658-672.

AMA Style

Johnson CH, Manna SK, Krausz KW, Bonzo JA, Divelbiss RD, Hollingshead MG, Gonzalez FJ. Global Metabolomics Reveals Urinary Biomarkers of Breast Cancer in a MCF-7 Xenograft Mouse Model. Metabolites. 2013; 3(3):658-672.

Chicago/Turabian Style

Johnson, Caroline H.; Manna, Soumen K.; Krausz, Kristopher W.; Bonzo, Jessica A.; Divelbiss, Raymond D.; Hollingshead, Melinda G.; Gonzalez, Frank J. 2013. "Global Metabolomics Reveals Urinary Biomarkers of Breast Cancer in a MCF-7 Xenograft Mouse Model." Metabolites 3, no. 3: 658-672.


Metabolites EISSN 2218-1989 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert